|
시장보고서
상품코드
1812457
세계의 내분비 치료제 시장 : 치료 영역별, 투여 경로별, 연령층별, 유통 채널별, 최종 사용자별, 지역별Endocrinology Drug Market, By Therapy Area, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Geography |
||||||
세계의 내분비 치료제 시장은 2025년 741억 1,000만 달러로 추정되고, 2023년까지 995억 1,000만 달러에 이를 전망으로, 2025년부터 2032년까지 연평균 성장률(CAGR) 4.3%로 성장이 예측되고 있습니다.
| 보고 범위 | 보고서 세부정보 | ||
|---|---|---|---|
| 기준연도 | 2024년 | 2025년 시장 규모 | 741억 1,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2020-2024년 |
| 예측기간 : 2025-2032년 CAGR : | 4.30% | 2032년 가치 예측 | 995억 1,000만 달러 |
내분비 치료제 시장은 세계에서 수백만 명이 앓고 있는 호르몬 장애와 대사성 질환을 다루는 중요한 치료 분야입니다. 내분비학은 당뇨병, 갑상선 기능 장애, 성장 호르몬 결핍, 골다공증, 비만, 생식 호르몬 불균형 등 호르몬 생산 샘과 그 관련 질환에 대한 연구를 포함합니다. 이 지역의 의약품은 생명 공학의 진보, 맞춤형 의료 접근법, 혁신적인 약물 전달 시스템에 견인되어 현저한 진화를 이루고 있습니다.
현대 내분비 치료제는 인슐린 유사체, GLP-1 수용체 작용제, SGLT-2 억제제, 갑상선 호르몬 보충제, 비스포스포네이트, 호르몬 보충 요법 등 다양한 약물 클래스에 걸쳐 있습니다. 시장의 복잡성은 소아의 성장 장애에서 노인의 대사 질환에 이르기까지 맞춤형 치료 요법이 필요한 다양한 환자 집단에 기인합니다. 지속적인 포도당 모니터링, 스마트 인슐린 전달 시스템, 바이오마커 주도형 진단의 기술 혁신은 치료 패러다임에 혁명을 일으켜 정밀의료 접근을 가능하게 합니다. 게다가 생활습관과 관련된 내분비 질환, 특히 당뇨병과 비만의 유병률 증가로 효능 프로파일이 개선되고 부작용이 감소된 차세대 치료제 개발을 위한 연구 투자와 규제 당국의 중점적인 대처가 강화되고 있습니다.
시장 역학
세계 내분비 치료제 시장은 서로 관련된 여러 요인들에 의해 강력한 성장을 이루고 있습니다. 주요 시장 성장 촉진요인으로는 세계적인 당뇨병 이환율의 상승이 포함되어 있으며, 이환 환자 수는 5억 명을 넘어 혁신적인 포도당 관리 솔루션, 인슐린 요법, 병용 요법에 대한 큰 수요를 창출하고 있습니다. 노인 인구는 갑상선 장애, 골다공증, 호르몬 균형의 혼란에 대한 감수성이 높고 장기적인 약물 개입이 필요하기 때문에 인구 역학의 고령화가 시장 확대에 크게 기여하고 있습니다. 서방형 메커니즘, 바이오시밀러 개발, 신규 전달 시스템 등 약물 제형의 기술적 진보는 환자의 컴플라이언스와 치료 성적을 향상시키면서 시장 혁신을 촉진합니다.
그러나 시장 개척은 특히 복잡한 생물제제와 병용요법에 있어서 제품 출시를 늦추고 개발 비용을 증대시키는 엄격한 규제 당국의 승인 프로세스 등 상당한 억제요인에 직면하고 있습니다. 블록버스터 내분비 치료제의 특허가 끊어지면 오리지네이터 기업에 가격 압력과 시장 점유율 저하를 가져오고 의료 비용 억제 정책은 세계적으로 상환 정책과 접근성에 영향을 미치고 있습니다.
또한, 생물학적 제제와 관련된 제조 복잡성, 공급망 취약성, 품질 관리 요구사항은 사업 운영 과제가 되고 있습니다. 하지만 당뇨병이나 대사성 질환이 급증하고 있음에도 불구하고 치료 보급률이 낮은 신흥 경제 국가의 미개척 시장을 통해 큰 비즈니스 기회가 생길 가능성도 있습니다. 유전자 검사 및 바이오마커 식별을 활용한 개인화된 의료 접근법은 표적 치료제에 유리한 전망을 제공합니다. 원격 의료 플랫폼과 AI를 통한 치료 최적화와 같은 디지털 건강 통합은 새로운 수익원을 창출하고 환자 참여를 강화함으로써 기존의 과제에도 불구하고 내분비 치료제 시장을 지속적인 성장으로 자리매김하고 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계 내분비 치료제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모(10억 달러)와 연간 평균 성장률(CAGR%)을 제공합니다.
- 다양한 부문에 걸쳐 잠재적인 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안의 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 매개변수를 바탕으로 세계 내분비 치료제 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진은 미래의 제품 상시, 타이핑, 시장 확대, 마케팅 전술에 관한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참여자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계 내분비 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사 결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 합병과 인수 시나리오
- 업계 동향
제4장 세계의 내분비 치료제 시장, 치료 영역별, 2020-2032년
- 당뇨병 관리약
- 갑상선 질환약
- 성장호르몬 관련 약
- 부신장애제
- 생식 내분비제
- 칼슘 및 골대사약
제5장 세계의 내분비 치료제 시장, 투여 경로별, 2020-2032년
- 경구
- 비경구
- 경피(패치 및 젤)
- 비강
- 기타(예 : 설하, 직장)
제6장 세계의 내분비 치료제 시장, 연령층별, 2020-2032년
- 소아
- 성인
- 고령자
제7장 세계의 내분비 치료제 시장, 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 내분비 치료제 시장, 최종 사용자별, 2020-2032년
- 병원 및 진료소
- 전문 내분비 센터
- 외래수술센터(ASC)
- 재택치료
- 기타(학술 및 연구 기관 등)
제9장 세계의 내분비 치료제 시장, 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제10장 경쟁 구도
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc
- Merck & Co Inc
- Novartis AG
- AstraZeneca plc
- AbbVie Inc
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
- Bayer AG
제11장 분석가 추천
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제12장 참고문헌과 조사방법
- 참고문헌
- 조사 방법
- 출판사에 대해
Endocrinology Drug Market is estimated to be valued at USD 74.11 Bn in 2025 and is expected to reach USD 99.51 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 74.11 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 4.30% | 2032 Value Projection: | USD 99.51 Bn |
The global endocrinology drug market represents a critical therapeutic segment addressing hormonal disorders and metabolic diseases that affect millions worldwide. Endocrinology encompasses the study of hormone-producing glands and their associated disorders, including diabetes mellitus, thyroid dysfunction, growth hormone deficiencies, osteoporosis, obesity, and reproductive hormone imbalances. The pharmaceutical landscape within this domain has witnessed remarkable evolution, driven by advancing biotechnology, personalized medicine approaches, and innovative drug delivery systems.
Modern endocrinology therapeutics span across various drug classes including insulin analogues, GLP-1 receptor agonists, SGLT-2 inhibitors, thyroid hormone replacements, bisphosphonates, and hormone replacement therapies. The market's complexity stems from diverse patient populations requiring tailored treatment regimens, ranging from pediatric growth disorders to geriatric metabolic conditions. Technological breakthroughs in continuous glucose monitoring, smart insulin delivery systems, and biomarker-driven diagnostics have revolutionized treatment paradigms, enabling precision medicine approaches. Additionally, the growing prevalence of lifestyle-related endocrine disorders, particularly diabetes and obesity, has intensified research investments and regulatory focus on developing next-generation therapeutics with improved efficacy profiles and reduced adverse effects.
Market Dynamics
The global endocrinology drug market experiences robust growth driven by multiple interconnected factors that shape its trajectory. Primary market drivers include the escalating prevalence of diabetes worldwide, with over 500 million affected individuals creating substantial demand for innovative glucose management solutions, insulin therapies, and combination treatments. Aging demographics contribute significantly to market expansion as elderly populations exhibit higher susceptibility to thyroid disorders, osteoporosis, and hormonal imbalances requiring long-term pharmaceutical interventions. Technological advancements in drug formulation, including extended-release mechanisms, biosimilar development, and novel delivery systems, drive market innovation while improving patient compliance and therapeutic outcomes.
However, the market growth faces considerable restraints including stringent regulatory approval processes that delay product launches and increase development costs, particularly for complex biologics and combination therapies. Patent expirations of blockbuster endocrinology drugs create pricing pressures and market share erosion for originator companies, while healthcare cost containment measures globally impact reimbursement policies and accessibility.
Additionally, manufacturing complexities associated with biologic drugs, supply chain vulnerabilities, and quality control requirements pose operational challenges. Nevertheless, significant opportunities emerge through untapped markets in developing economies where diabetes and metabolic disorders are rapidly increasing but treatment penetration remains low. Personalized medicine approaches leveraging genetic testing and biomarker identification present lucrative prospects for targeted therapeutics. Digital health integration, including telemedicine platforms and AI-driven treatment optimization, creates new revenue streams and enhances patient engagement, positioning the endocrinology drug market for sustained growth despite existing challenges.
Key features of the study
- This report provides in-depth analysis of the global endocrinology drug market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global endocrinology drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Pfizer Inc, Merck & Co Inc, Novartis AG, AstraZeneca plc, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Ipsen Pharma, Teva Pharmaceutical Industries Ltd, Amgen Inc, and Bayer AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global endocrinology drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrinology drug market
Market Segmentation
- Therapy Area Insights (Revenue, USD Bn, 2020 - 2032)
- Diabetes Management Drugs
- Insulin (short-acting, long-acting, and premixed)
- Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
- GLP-1 Receptor Agonists
- Other Combination Therapies
- Thyroid Disorder Drugs
- Hypothyroidism Treatments (levothyroxine and liothyronine)
- Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
- Growth Hormone Related Drugs
- Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
- Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
- Adrenal Disorder Drugs
- Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
- Addison's Disease Treatments (glucocorticoids and mineralocorticoids)
- Congenital Adrenal Hyperplasia Drugs
- Reproductive Endocrinology Drugs
- Men's Health (testosterone therapies and anti-androgens)
- Women's Health (estrogen therapies, progesterone therapies, etc.)
- Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
- Calcium and Bone Metabolism Drugs
- Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
- Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Transdermal (patches and gels)
- Nasal
- Others (e.g., sublingual, rectal)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Endocrine Centers
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc
- Merck & Co Inc
- Novartis AG
- AstraZeneca plc
- AbbVie Inc
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Endocrinology Drug Market, By Therapy Area
- Global Endocrinology Drug Market, By Route of Administration
- Global Endocrinology Drug Market, By Age Group
- Global Endocrinology Drug Market, By Distribution Channel
- Global Endocrinology Drug Market, By End User
- Global Endocrinology Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Endocrinology Drug Market, By Therapy Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Diabetes Management Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Insulin (short-acting, long-acting and premixed)
- Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
- GLP-1 Receptor Agonists
- Other Combination Therapies
- Thyroid Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hypothyroidism Treatments (levothyroxine and liothyronine)
- Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
- Growth Hormone Related Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
- Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
- Adrenal Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
- Addison's Disease Treatments (glucocorticoids, mineralocorticoids)
- Congenital Adrenal Hyperplasia Drugs
- Reproductive Endocrinology Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Men's Health (testosterone therapies and anti-androgens)
- Women's Health (estrogen therapies, progesterone therapies, etc.)
- Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
- Calcium and Bone Metabolism Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
- Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)
5. Global Endocrinology Drug Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Transdermal (patches and gels)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (e.g., sublingual and rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Endocrinology Drug Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Endocrinology Drug Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Endocrinology Drug Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Endocrine Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Endocrinology Drug Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us
